Scholarlink

Background <p>There is limited evidence on the efficacy and safety of single anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S) in treating type 2 diabetes mellitus (T2DM) in patients with body mass index (BMI) &lt; 35&#xa0;kg/m<sup>2</sup>.</p> Methods <p>This study included clinical data from 22 T2DM patients with BMI &lt; 35&#xa0;kg/m<sup>2</sup> who received SADI-S treatment. Changes in diabetes-related indicators, weight-related indicators, and patient nutritional outcomes were analyzed.</p> Results <p>SADI-S was successfully performed in all 22 cases, with no conversions to laparotomy or resulting deaths. The incidence of surgical complications was 4.54% (1/22). One-year postsurgery, there was a significant decrease in BMI from 32.42 ± 2.18 to 22.11 ± 1.86&#xa0;kg/m<sup>2</sup> (<i>P</i> &lt; 0.05) and a significant decrease in mean HbA1c from 8.76 ± 1.74 to 5.25 ± 0.76% (<i>P</i> &lt; 0.05). The %EWL and %TWL were 145.78 ± 35.97% and 31.60 ± 6.34% respectively at 1&#xa0;year. The remission rate for T2DM was 94.7% (18/19) at 1&#xa0;year. Following SADI-S, the incidence rates of zinc deficiency and vitamin D deficiency at 1&#xa0;year were 38.46% (5/13) and 30.77% (4/13), respectively, significantly higher than presurgery.</p> Conclusions <p>SADI-S is considered an efficient, safe, and feasible surgical approach for patients with T2DM and a BMI &lt; 35&#xa0;kg/m<sup>2</sup>. Nevertheless, additional research, including potentially multi-center collaborative studies, is warranted to assess the procedure’s long-term outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

One-Year Outcomes of SADI-S in Chinese Patients with Type 2 Diabetes and BMI < 35 kg/m2: A Single-Center Retrospective Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月26日

查看全文
  • Zheng Zhang,
  • Tao Jiang

摘要

Background

There is limited evidence on the efficacy and safety of single anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S) in treating type 2 diabetes mellitus (T2DM) in patients with body mass index (BMI) < 35 kg/m2.

Methods

This study included clinical data from 22 T2DM patients with BMI < 35 kg/m2 who received SADI-S treatment. Changes in diabetes-related indicators, weight-related indicators, and patient nutritional outcomes were analyzed.

Results

SADI-S was successfully performed in all 22 cases, with no conversions to laparotomy or resulting deaths. The incidence of surgical complications was 4.54% (1/22). One-year postsurgery, there was a significant decrease in BMI from 32.42 ± 2.18 to 22.11 ± 1.86 kg/m2 (P < 0.05) and a significant decrease in mean HbA1c from 8.76 ± 1.74 to 5.25 ± 0.76% (P < 0.05). The %EWL and %TWL were 145.78 ± 35.97% and 31.60 ± 6.34% respectively at 1 year. The remission rate for T2DM was 94.7% (18/19) at 1 year. Following SADI-S, the incidence rates of zinc deficiency and vitamin D deficiency at 1 year were 38.46% (5/13) and 30.77% (4/13), respectively, significantly higher than presurgery.

Conclusions

SADI-S is considered an efficient, safe, and feasible surgical approach for patients with T2DM and a BMI < 35 kg/m2. Nevertheless, additional research, including potentially multi-center collaborative studies, is warranted to assess the procedure’s long-term outcomes.